Coenzyme Q10

Alternative Medicine Review

Volumn 12, Issue 2, 2007, Pages 159-168

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DOXORUBICIN; FUROSEMIDE; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; ANTIOXIDANT ACTIVITY; ASTHMA; BREAST CANCER; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DYSLIPIDEMIA; FRIEDREICH ATAXIA; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; HYPERTENSION; HYPERTHYROIDISM; KIDNEY FAILURE; MALE INFERTILITY; MELANOMA; METASTASIS; MIGRAINE; NAUSEA; PARKINSON DISEASE; PERIODONTAL DISEASE; RASH; REVIEW; THYROID DISEASE; ANIMAL; ARTICLE; COENZYME;

ANIMALS; COENZYMES; HUMANS; UBIQUINONE;

EID: 34547490883     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Olson RE, Rudney H. Biosynthesis of ubiquinone. Vitam Horm 1983;40:1-43.
2. Willis R, Anthony M, Sun L, et al. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. Biofactors 1999;9:359-363.
3. Montero R, Artuch R, Briones P, et al. Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders. Biofactors 2005;25:109-115.
4. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;15:S265-S272.
5. Nakamura R, Littarru GP, Folkers K, Wilkinson EG. Deficiency of coenzyme Q in gingiva of patients with periodontal disease. Int J Vitam Nutr Res 1973;43:84-92.
6. Gazdik F, Gvozdjakova A, Nadvornikova R, et al. Decreased levels of coenzyme Q(10) in patients with bronchial asthma. Allergy 2002;57:811-814.
7. Menke T, Niklowitz P, Reinehr T, et al. Plasma levels of coenzyme Q10 in children with hyperthyroidism. Horm Res 2004;61:153-158.
8. Mancini A, Milardi D, Conte G, et al. Coenzyme Q10: another biochemical alteration linked to infertility in variocele patients? Metabolism 2003;52:402-406.
9. Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 1988;153:888-896.
10. Gaby AR. The role of Coenzyme Q10 in clinical medicine: Part I. Altern Med Rev 1996;1:11-17.
11. Gaby AR. The role of coenzyme Q10 in clinical medicine: Part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med Rev 1996;1:168-175.
12. Quinzii CM, DiMauro S, Hirano M. Human coenzyme Q10 deficiency. Neurochem Res 2007;32:723-727.
13. Weber C, Bysted A, Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutr Res 1997;17:941-945.
14. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, et al. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med 1997;22:1195-1202.
15. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998;68:109-113.
16. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40:445-453.
17. Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994;15:S273-S280.
18. Lyon W, Van den Brink O, Pepe S, et al. Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10. Asia Pac J Clin Nutr 2001;10:212-215.
19. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr 2007;12:62-68.
20. Li W, Li K, Huang YF. Biological function of CoQ10 and its effect on the quality of spermatozoa. Zhonghua Nan Ke Xue 2006;12:1119-1122. [Article in Chinese]
21. Battino M, Bompadre S, Politi A, et al. Antioxidant status (CoQ10 and Vit. E levels) and immunohistochemical analysis of soft tissues in periodontal diseases. Biofactors 2005;25:213-217.
22. Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 1994;15:S165-S175.
23. Folkers K, Littarru GP, Ho L, et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch 1970;40:380-390.
24. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 1985;82:901-904.
25. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 2003;18:79-89.
26. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006;12:464-472.
27. National Center for Biotechnology Information (NCBI), National Library of Medicine (PubMed) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD= search&DB=mesh [Accessed May 5, 2007]
28. Langsjoen PH, Folkers K, Lyson K, et al. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 1988;66:583-590.
29. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:521-523.
30. Hargreaves IP, Duncan AJ, Heales SJ, Land JM. The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf 2005;28:659-676.
31. Folkers K, Langsjoen P, Willis R, et al. Lovostatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990;87:8931-8934.
32. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-229.
33. Okamoto H, Kawaguchi H, Togashi H, et al. Effect of coenzyme Q10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats. Biochem Med Metab Biol 1991;45:216-226.
34. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
35. Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007;21:297-306.
36. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247-251.
37. Kogan AKh, Syrkin AL, Drinitsina SV, Kokanova IV. The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort. Patol Fiziol Eksp Ter 1999;4:16-19. [Article in Russian]
38. Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1998;12:347-353.
39. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report) - antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J Exp Med 1983;141:S453-S463.
40. Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann Thorac Surg 1982;33:145-151.
41. Zhou M, Zhi Q, Tang Y, et al. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J Cardiovasc Surg (Torino) 1999;40:355-361.
42. Oda T, Hamamoto K. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jpn Circ J 1984;48:1387.
43. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 1999;9:267-272.
44. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from Parkinsonian and nonparkinsonian subjects. Ann Neurol 1997;42:261-264.
45. Sohmiya M, Tanaka M, Tak NW, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004;223:161-166.
46. Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-795.
47. Horstink MW, van Engelen BG. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol 2003;60:1170-1172.
48. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003;341:201-204.
49. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004;188:491-494.
50. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
51. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's Disease. Neurology 2001;57:397-404.
52. Nishikawa Y, Takahashi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome C oxidase deficiency: a 31P NMR study. Neurology 1989;39:399-403.
53. Goda S, Hamada T, Ishimoto S, et al. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:62-63.
54. Berbel-Garcia A, Barbera-Farre HR, Etessam JP, et al. Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitchondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Clin Neuropharmacol 2004;27:187-191.
55. Gold R, Seibel P, Reinelt G, et al. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q10. Eur Neurol 1996;36:191-196.
56. Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-685.
57. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1995;1271:281-286.
58. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-218.
59. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center, double blind trial. J Neurol Sci 1990;100:70-78.
60. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-177.
61. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-1508.
62. Rusciani L, Proietti I, Rusciani A, et al. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54:234-241.
63. Palan PR, Mikhail MS, Shaban DW, Romney SL. Plasma concentrations of coenzyme Q10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer. Eur J Cancer Prev 2003;12:321-326.
64. Domae N, Sawada H, Matsuyama E, et al. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep 1981;65:79-91.
65. Karlsson J, Folkers K, Astrum H, et al. Effect of adriamycin on heart and skeletal muscle coenzyme Q (CoQ10) in man. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol. 5. Amsterdam, Holland: Elsevier/North-Holland Biomedical Press; 1986:247-256.
66. Judy WV, Hall JH, Dugan W, et al. Coenzyme Q10 reduction of adriamycin cardiotoxicity. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol. 4. Amsterdam, Holland: Elsevier/North-Holland Biomedical Press; 1984:231-241.
67. Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 2004;22:4418-4424.
68. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999;49:324-329.
69. Watts GF, Playford DA, Croft KD, et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002;45:420-426.
70. Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-1142.
71. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-179.
72. Mancini A, De Marinis L, Oradei A, et al. Coenzyme Q10 concentrations in normal and pathological human seminal fluid. J Androl 1994;15:591-594.
73. Mancini A, De Marinis L, Littarru GP, Balercia G. An update of coenzyme Q10 implications in male infertility: biochemical and therapeutic aspects. Biofactors 2005;25:165-174.
74. Balercia G, Mosca F, Mantero F, et al. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004;81:93-98.
75. Barbieri B, Lund B, Lundstrom B, Scaglione F. Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers - a single blind placebo-controlled and randomized clinical study. Biofactors 1999;9:351-357.
76. Cohen IS, Anderson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986;315:628-630.
77. Rabing Christensen E, Stegger M, Jensen-Fangel S, et al. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004;39:1371-1379.
78. Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991;176:786-791.
79. Gvozdjakova A, Kucharska J, Bartkovjakova M, et al. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25:235-240.
80. Mano T, Iwase K, Hayashi R, et al. Vitamin E and coenzyme Q concentrations in the thyroid tissues of patients with various thyroid disorders. Am J Med Sci 1998;315:230-232.
81. Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1976;14:715-719.
82. Wilkinson EG, Arnold RM, Folkers K. Treatment of periodontal and other soft tissue diseases of the oral cavity with coenzyme Q. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol. 1. Amsterdam, Holland: Elsevier/North-Holland Biomedical Press; 1977:251-265.
83. Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975;12:111-123.
84. Singh RB, Kumar A, Niaz MA, et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with end-stage renal failure. J Nutr Environ Med 2003;13:13-22.
85. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: a four-year follup-up. Arch Neurol 2005;62:621-626.
86. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-141.
87. Noia G, Littarru GP, De Santis M, et al. Coenzyme Q10 in pregnancy. Fetal Diagn Ther 1996;11:264-270.
88. Freeman LM. Interventional nutrition for cardiac disease. Clin Tech Small Anim Pract 1998;13:232-237.
89. Otrocka-Domagala I, Rotkiewicz T, Karpinska J, et al. The effect of coenzyme Q10 and vitamin E on the regeneration of skeletal muscles in pigs. Pol J Vet Sci 2004;7:295-303.
90. Lelli JL, Drongowski RA, Gastman B, et al. Effects of coenzyme Q10 on the mediator cascade of sepsis. Circ Shock 1993;39:178-187.
91. Harman J, Ward M. The role of nutritional therapy in the treatment of equine Cushing's syndrome and laminitis. Altern Med Rev 2001:6:S4-S16.
92. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-S144.
93. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Res Commun Chem Pathol Pharmacol 1977;17:157-164.
94. Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975;12:533-540.
95. Wickersham R. Drug Facts and Comparisons, St. Louis, MO: Wolters Kluwer Health 2006:1118.